Roche Mircera Launch Blocked By Permanent Injunction
This article was originally published in The Pink Sheet Daily
Executive Summary
Ruling comes just ahead appeals-court hearing on epoetin follow-on.
You may also be interested in...
Praluent Injunction Goes Unmentioned At PCSK9 Patent Case Appeal
Three-judge US federal appellate panel focuses on evidentiary rulings and patent validity in the dispute between Repatha marketer Amgen and Sanofi/Regeneron; lower court’s permanent injunction barring sales of Praluent did not come up at oral arguments.
Patent Power: Roche Concedes Case Over Amgen's EPO
Roche will not launch its anemia drug Mircera in the U.S. until Amgen's latest patent expires in 2015 unless it obtains a license.
Patent Power: Roche Concedes Case Over Amgen's EPO
Roche will not launch its anemia drug Mircera in the U.S. until Amgen's latest patent expires in 2015 unless it obtains a license.